Purpose To investigate the development of polypoidal lesions using indocyanine green angiography (IA) in eyes with typical age-related macular degeneration (AMD). Methods We retrospectively reviewed the medical records of 47 consecutive patients (47 eyes) with typical AMD who had been followed up with IA for at least 2 years. Results At the initial visit, although all eyes showed classic and/or occult choroidal neovascularization (CNV) associated with AMD, no eyes showed polypoidal lesions by IA. However, during follow-up, 13 (27.7%) of the 47 eyes did show polypoidal lesions. All polypoidal lesions developed at the edge of persistent CNV or, more often, at the terminus of recently progressed CNV. Of 12 eyes with a final lesion area 48 disc area, 7 (58.3%) showed newly developed polypoidal lesions. In the eyes with these newly developed polypoidal lesions, the mean area of the vascular lesion had extended significantly from 10.50±7.88 mm 2 to 20.87±10.21 mm 2 during follow-up (P ¼ 0.0018). Conclusion The current observation suggests that IA of active AMD sometimes reveals polypoidal lesions if there is progression of the CNV in the subretinal pigment epithelium space.
Introduction
Initially, polypoidal choroidal vasculopathy (PCV) was described as a new clinical entity with a unique form of choroidal vascular abnormality. [1] [2] [3] As Uyama et al 4, 5 proposed that PCV is a variant of choroidal neovascularization (CNV) in exudative age-related macular degeneration (AMD), it has been generally believed that the vascular components in PCV are a type of CNV, although the pathogenesis of PCV is not fully understood. 6, 7 In general, PCV is diagnosed when polypoidal lesions are seen by indocyanine green angiography (IA) at the terminus of typical branching vascular networks. 8 IA is essential for the study of the vascular lesion of PCV because most of the vascular components of PCV are located beneath the retinal pigment epithelium; 8 hence, with fundus examination or fluorescein angiography (FA), it is often difficult to distinguish macular PCV from exudative AMD. [9] [10] [11] An increasing number of reports has recently shown that anti-vascular endothelial growth factor (VEGF) therapy can reduce the exudative change and lesion size in exudative AMD, and can result in visual recovery. [12] [13] [14] [15] [16] [17] [18] However, some eyes with exudative AMD are refractory to repeated anti-VEGF therapy. 19, 20 Clinicians sometimes see cases of typical AMD with a large lesion that shows a poor response to treatment and that shows progression, which results in a poor visual prognosis. When we performed IA on such AMD cases with large lesions, we sometimes noted knob-like hyperfluorescent lesions at the end of progressing CNV, which resembled the polypoid lesions typically seen in PCV. 21 Cho et al 19 reported that IA revealed these polypoidal lesions in 12 cases of exudative AMD with a poor response to anti-VEGF therapy.
In the clinical setting, FA is essential to make a diagnosis and to evaluate lesion size and its activity in exudative AMD. 22 Even in exudative AMD, IA often provides useful information about vascular lesions, especially those located beneath the retinal pigment epithelium. 23, 24 So far, however, limited information is available using IA on long-term observations of the vascular components in typical AMD. In this study, we studied the vascular lesions of typical AMD using IA, to elucidate the rate and characteristics of eyes that were initially diagnosed as having typical AMD and that subsequently developed polypoidal lesions.
Patients and methods
For this observational case study, we retrospectively reviewed the medical records of 47 consecutive patients (47 eyes) with typical AMD who initially visited the Macula Service, Department of Ophthalmology, Kyoto University Hospital between October 2004 and October 2007 and whose eyes had been examined with both FA and IA for more than 2 years after the initial visit. During this period, 116 patients with typical AMD initially visited our clinic. In all, 69 patients were excluded from the current study because of a short follow-up period or because they lacked FA or IA during the more than 2 years since the initial visit. When both eyes showed typical AMD, only one eye was selected randomly for inclusion in the current study. This study was approved by the Institutional Review Board at the Kyoto University Graduate School of Medicine and adhered to the tenets of the Declaration of Helsinki.
The diagnosis of typical AMD was made based on fundus photographs, FA, IA, and optical coherence tomography (OCT), which showed type 1 and/or type 2 CNV. Eyes with other macular abnormalities (such as PCV, retinal angiomatous proliferation, pathological myopia, idiopathic CNV, presumed ocular histoplasmosis, angioid streaks, and other secondary CNV) were excluded from the current study. When reddish-orange nodules were seen by ophthalmoscopic examination or polypoidal lesions were seen by IA, the eye was excluded from the current study. Eyes that had been previously treated with focal laser photocoagulation, photodynamic therapy, vitrectomy, radiation therapy, or anti-VEGF therapy were also excluded from this study.
At the initial visit, all patients had undergone a comprehensive ophthalmological examination, including measurement of best-corrected visual acuity (VA), determination of intraocular pressure, indirect ophthalmoscopy, slitlamp biomicroscopy with a contact lens, and OCT. After fundus photographs were taken, FA and IA were performed on each patient using a confocal laser scanning system (HRA-2, Heidelberg Engineering, Dossenheim, Germany). VA measurement and OCT examination were performed on each patient at each follow-up visit; FA and IA were performed if necessary, and all patients in the current study were examined with both FA and IA several times during their follow-up.
In this study, the greatest linear dimension (GLD) and area of the lesion were determined based on the IA using software that was built into the HRA-2. GLD was defined as covering the entire CNV lesion, including type 1 and type 2 CNV, polypoidal lesions, and the branching vascular network. The area of the CNV lesion was measured manually using software in HRA-2. Pigment epithelial detachment, without underlying CNV, was not included in the measurement of GLD or in the area of the lesion. In the current study, one optic disc area (DA) is considered to be 2.54 mm 2 on the basis of one optic disc diameter being 1.8 mm.
Using OCT images, we performed two measurements using a caliper that was built into the software of the OCT machine; using these calipers, foveal thickness and thickness of the neurosensory retina in the fovea were measured. Foveal thickness was defined as the distance between the vitreoretinal interface and the retinal pigment epithelium; thickness of the neurosensory retina was defined as the distance between the vitreoretinal interface and the tip of the outer portion of the inner and outer segments of the photoreceptors.
In the current study, measurement values obtained at the initial visit were compared with those obtained at the final examination. To evaluate progression of the vascular lesions, the initial area of the CNV lesion and that of the GLD were compared with final values. To evaluate activity of the disease, we also compared the initial OCT measurement (foveal thickness and thickness of the neurosensory retina) with values obtained at the final visit. To compare the difference in VA, vision as measured with a Landolt chart was converted to a logarithm of the minimal angle of resolution (logMAR).
Statistical analysis was performed using software designed for this purpose (StatView, version 5.0; SAS Institute, Cary, NC, USA). A P-value o0.05 was considered to be statistically significant.
Results
In the current study, 47 eyes of 47 patients (36 men and 11 women) with typical AMD were examined; the patients ranged in age from 56 to 90 years (72.8±7.5 years). The follow-up period ranged from 24 to 59 months (43.9 ± 10.3 months). All patients were examined with FA and IA repeatedly during their follow-up, ranging from 2 to 10 times (4.6 ± 1.8 times). Table 1 shows characteristics of patients who were eligible for this study. Mean baseline VA (logMAR) was 0.70±0.53, and the mean initial areas of the lesion and GLD were At the initial visit, although all eyes of the patients involved showed classic and/or occult CNV associated with AMD, no eyes showed polypoidal lesions by IA. During the follow-up period, 34 eyes were initially treated with photodynamic therapy, and 5 were initially treated with anti-VEGF therapy. In spite of these treatments, however, some eyes with typical AMD showed extension of the vascular components with an exudative change. The mean area of the neovascularization increased from 8.68±7.75 mm 2 to 14.28 ± 10.57 mm 2 during follow-up (Po0.0001). Moreover, during the follow-up, 13 (27.7%) of the 47 eyes showed polypoidal lesions by IA. All of these polypoidal lesions developed either at the edge of persistent CNV (Figure 2) or, more often, at the terminus of the newly progressed CNV (Figures 3 and 4) . Of 12 eyes with a final CNV area 48 DA, 7 (58.3%) showed newly developed polypoidal lesions (Figure 1) .
Depending on the development of polypoidal lesions, we divided our patients with typical AMD into two groupsFthose with polypoidal lesions (n ¼ 13) and those without polypoidal lesions (n ¼ 34). Table 1 shows baseline and final measurement values of each group. There were no significant differences in gender or age between these two groups (P ¼ 0.9739 and P ¼ 0.8913).
Furthermore, there were no differences in VA (P ¼ 0.6234), area of lesion (P ¼ 0.3262), or GLD (P ¼ 0.3269) at the initial visit. The mean area of the lesion in eyes with polypoidal lesions enlarged significantly from 10.50 ± 7.88 mm 2 to 20.87 ± 10.21 mm 2 during the follow-up (P ¼ 0.0018). The mean GLD in eyes with polypoidal lesions also progressed significantly from 4231±1692 mm to 5880±1947 mm (P ¼ 0.0032). Although mean areas of the lesion and GLD were increased in eyes without polypoidal lesions, the increases were significantly greater in eyes that developed polypoidal lesions (P ¼ 0.0036 and P ¼ 0.0035). In eyes with polypoidal lesions, however, final VA was not statistically different compared with that in eyes without polypoidal lesions (P ¼ 0.2303).
Discussion
PCV was first described as a new clinical entity with an associated unique form of choroidal vascular abnormality. [1] [2] [3] Subsequently, however, based on histological specimens and OCT examinations, PCV is considered to be a unique form of CNV. 25, 26 In general, presumed exudative AMD is diagnosed as PCV when IA shows polypoidal lesions at the terminus of the branching vascular network. 8 In PCV, IA is essential to make the diagnosis and to precisely evaluate the entire vascular lesion. 8 In the current study, polypoidal lesions developed in 27.7% of eyes with typical AMDFeyes that had shown no polypoidal lesions at the initial visit. All polypoidal lesions developed at the edge of persistent CNV or, more often, at the terminus of recently progressed CNV. The current observation suggests that active AMD may show polypoidal lesions, if there is progression in the subretinal pigment epithelium space.
The tip of the extending CNV, which is the most active lesion, typically shows vigorous leakage on FA. 22 Even if the CNV is located beneath the retinal pigment epithelium, it sometimes shows a 'classic' appearance, as proposed in the updated clinicopathological classification of subretinal neovascularization by Gass. 27 As molecules of indocyanine green readily attach to serum albumin, 28 vigorous leakage is not seen usually by IA, even from active CNV, 23, 24, 29 but CNV that is stained by indocyanine green may well appear as knobbed hyperfluorescent spots on IA. 30 In our patients, the tips of progressive CNV associated with AMD that showed focal hyperfluorescence on IA might appear to be polypoidal lesions.
Another interpretation is also possible. We can assume that the branching vascular network and polypoidal lesions represent a variant of type 1 CNV associated with exudative AMD. 4, 5 In the clinical setting, when no polypoidal lesions are seen, it is difficult to distinguish the branching vascular network from the type 1 CNV that may be associated with AMD. 31 Clinically, some polypoidal lesions do regress spontaneously or, more commonly, after photodynamic therapy, but they tend to recur at the same location or at other terminals of the branching vascular network. 6, 9, 32 In the current study, a diagnosis of typical AMD was made in all eyes, based on the initial IA. It is possible that some of our patients actually had PCV which was misdiagnosed, and that some showed polypoidal lesions during the follow-up. Recently, Maruko et al 33 reported that among 349 patients with neovascular AMD, 20 (5.7%) had 1 eye with PCV, whereas the fellow eye showed typical AMD, but that PCV developed during the follow-up in 10 eyes that had typical AMD at the initial examination. As their patients had PCV lesions in the fellow eye, it is reasonable to assume that these eyes originally had PCV but did not meet the diagnostic criteria of PCV. 33 Our patients had been examined with both FA and IA for more than 2 years after the initial visit. In the current study, the rate of those eyes that were refractory to treatment or that showed a recurrence of CNV after the successful initial treatment might be relatively high. Recently, Cho et al 19 reported that polypoidal lesions were detected in 12 cases of exudative AMD with a poor response to anti-VEGF therapy. In their report, treatment with photodynamic therapy, photodynamic therapy/anti-VEGF combination therapy, or continued anti-VEGF monotherapy resulted in complete resolution of exudation in 9 of 12 eyes. In the current study, we showed that typical AMD refractory to treatment sometimes developed polypoidal lesions at the terminus of the newly progressed CNV. However, visual prognosis of these eyes was not poor. We treated eyes with polypoidal lesions primarily by photodynamic therapy or photodynamic therapy combined with anti-VEGF therapy. Today, anti-VEGF therapy is a primary treatment for typical AMD. In eyes with exudative AMD refractory to treatment, however, we suggest that clinicians should reconsider the treatment strategy after re-evaluation of the CNV by IA.
It is still controversial as to whether PCV is a distinct clinical entity or is simply a unique form of exudative AMD. 6 In Asian populations, a number of reports have shown that genetic variations in ARMS2 and CFH are strongly associated with both AMD and PCV. [34] [35] [36] [37] [38] In addition, Lima et al 39 recently reported that the PCV phenotype in Caucasian patients is associated with the three major AMD-associated loci, including CFH, ARMS2, and CFB/C2 genes, and they suggested that PCV and AMD are genetically similar in these tested loci. 
Eye
Although Kondo et al 40 have implicated the elastin gene as a susceptibility gene for PCV, it is generally believed that PCV and AMD share common genetic backgrounds, even though complications, treatment effect, and visual prognosis are somewhat different. 6, 11 Indeed, PCV is a distinct clinical entity, 9 although some advanced AMD cases do show features characteristic of PCV. 33 Limitations of the current study are its retrospective nature and the various treatment regimens used. In the current study, active AMD sometimes showed polypoidal lesions at the terminus of the vascular lesion, when the neovascularization showed progression in the subretinal pigment epithelium space. In the clinical setting, eyes with a small PCV lesion often maintain good VA for a protracted period of time. 41, 42 In contrast, cases of PCV with a large lesion that has a poor response to treatment and that shows progression, tend to have a poor visual prognosis. 21 Our findings suggest that advanced AMD overlaps with PCVFat least with PCV that has a large vascular lesion.
